Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent cause of chronic
liver disease (CLD). Currently, the only therapeutic recommendation available is a lifestyle …

Non-alcoholic fatty liver disease (NAFLD) is a multifaceted disease allied with various
metabolic disorders, obesity and dysbiosis. Gut microbiota plays an influential role in the …

Background and Aims The clinical efficacy of fecal microbiota transplantation (FMT) in
patients with non-alcoholic fatty liver disease (NAFLD) and the variant effects of FMT on lean …

Nonalcoholic fatty liver disease (NAFLD) is significantly on the rise, which will seriously
affect human health; yet, there is no approved drug for the treatment of NAFLD currently …

Chronic liver disease including non‐alcoholic fatty liver disease and alcohol‐related liver
disease is one of the most common diseases worldwide. The gut–liver axis plays an …

Introduction: Nonalcoholic fatty liver disease (NAFLD) is one of the most common and
increasing liver diseases worldwide with a prevalence of 20–33%. NAFLD may progress to …

Non-alcoholic fatty liver disease (NAFLD) represents an increasing cause of liver disease,
affecting one-third of the population worldwide. Despite many medications being in the …

Nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are some of the
most common liver diseases worldwide. The human gut microbiome is dynamic and shifts in …

Introduction: Gut microbiota is not only a taxonomic biologic ecosystem but is also involved
in human intestinal and extra-intestinal functions such as immune system modulation …

A growing body of evidence suggested that gut microbiota is associated with liver diseases
through the gut–liver axis. The imbalance of gut microbiota could be correlated with the …